Journal of Alzheimer's Disease
Published on Journal of Alzheimer's Disease (https://www.j-alz.com)

Home > Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.

TitleChanges in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease.
Publication TypeJournal Article
Year of Publication2016
AuthorsNovak, G, Fox, N, Clegg, S, Nielsen, C, Einstein, S, Lu, Y, Tudor, ICristina, Gregg, K, Di, J, Collins, P, Wyman, BT, Yuen, E, Grundman, M, H Brashear, R, Liu, E
JournalJ Alzheimers Dis
Volume49
Issue4
Pagination1123-34
Date Published2016
ISSN1875-8908
KeywordsAged, Alzheimer Disease, Antibodies, Monoclonal, Humanized, Apolipoprotein E4, Brain, Double-Blind Method, Female, Heterozygote, Humans, Least-Squares Analysis, Magnetic Resonance Imaging, Male, Nootropic Agents, Organ Size, Severity of Illness Index, Treatment Outcome
Abstract

BACKGROUND: Bapineuzumab, an anti-amyloid-β monoclonal antibody, was evaluated in two placebo-controlled trials in APOE*ɛ4 carriers and noncarriers, respectively, with Alzheimer's disease.

OBJECTIVES: A volumetric magnetic resonance imaging substudy was performed to determine if bapineuzumab altered brain volume rate of change.

METHODS: Bapineuzumab dosages included 0.5 mg/kg in carriers and 0.5 or 1.0 mg/kg in noncarriers, every 13 weeks for 78 weeks. Volumetric outcomes included annualized brain, ventricular, and mean hippocampal boundary shift integrals (BBSI; VBSI; HBSI) up to Week 71. Treatment differences were estimated using mixed models for repeated measures.

RESULTS: For BBSI and HBSI, there were no significant treatment-related differences within either study, but, compared to pooled carriers and noncarriers receiving placebo, noncarriers receiving1.0 mg/kg bapineuzumab had greater increases in these measures. Bapineuzumab-treated patients showed significantly greater VBSI rates compared with placebo for 0.5 mg/kg in carriers and 1.0 mg/kg (but not 0.5 mg/kg) in noncarriers.

CONCLUSIONS: Bapineuzumab produced an increase in ventricular volume compared with placebo. Etiology for this increase is unclear but may be related to amyloid-β clearance or its consequences.

DOI10.3233/JAD-150448
Alternate JournalJ. Alzheimers Dis.
PubMed ID26639957
E-mail Icon
Comment Icon
  • Comment
Bookmark Icon Bookmark Recommend Icon Recommend Follow Icon Follow
  • Comment
| Bookmark | Recommend | Follow

Source URL: https://www.j-alz.com/content/changes-brain-volume-bapineuzumab-mild-moderate-alzheimers-disease